In this study, we investigated the clinical effects of blood ultrafiltration therapy in patients with acute decompensated chronic heart failure. We enrolled 78 patients with acute decompensated chronic heart failure who were admitted to a hospital from September 2017 to December 2021, and divided them into two groups based on the digital randomization method. The FQ-16 heart failure ultrafiltration dehydrating device blood ultrafiltration therapy was administered to the observation group (39 patients) for 8-16 hours, while the control group (39 patients) received the stepped drug therapy. Echocardiography was used to assess the changes in cardiac function of the patients in both groups before and after treatment. The changes in urine volume, N-terminal pro-B-type natriuretic peptide (NT-proBNP), plasma renin, and serum creatinine levels were measured before and after the treatment to compare the overall response rate of the patients in both groups. The differences in left ventricular end-systolic dimension and left ventricular end-diastolic dimension and the ejection fraction between the groups before treatment were not statistically significant (P > 0.05), however, the left ventricular end-diastolic dimension in the observation group was significantly lower and the ejection fraction was significantly higher (P < 0.05) compared with that before treatment; the urine volume, N-terminal pro-B-type natriuretic peptide (NT-proBNP), plasma renin, and serum creatinine were significantly improved in both groups after treatment compared with that before treatment. All indexes in the observation group were better than those in the control group (P < 0.05), 74.36%. The overall response rate of the observation group was 94.87%, x2 = 4.843 and the difference between groups was statistically significant (P < 0.05). Blood ultrafiltration therapy for patients with acute decompensated chronic heart failure can improve their cardiac and renal functions, reduce NT-proBNP, reduce volume load, and enhance efficacy while ensuring high safety.

Department of Cardiology The 1st People's Hospital of Yangquan Yangquan China

Zobrazit více v PubMed

Baman JR, Ahmad FS. Heart Failure. JAMA. 2020;324:1015. doi: 10.1001/jama.2020.13310. PubMed DOI

Lacko S, Mlček M, Hála P, et al. Severe acute heart failure - experimental model with very low mortality. Physiol Res. 2018;67:555–562. doi: 10.33549/physiolres.933774. PubMed DOI

Njoroge JN, Teerlink JR. Pathophysiology and therapeutic approaches to acute decompensated heart failure. Circ Res. 2021;128:1468–1486. doi: 10.1161/CIRCRESAHA.121.318186. PubMed DOI PMC

Hála P, Kittnar O. Hemodynamic adaptation of heart failure to percutaneous venoarterial extracorporeal circulatory supports. Physiol Res. 2020 Nov 16;69:739–757. doi: 10.33549/physiolres.934332. PubMed DOI PMC

Heart failure Group, Cardiology Branch of Chinese Medical Association, Heart failure Professional Committee of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiovascular Diseases. Chinese Guidelines for Diagnosis and Treatment of heart failure 2018. Ch J Cardiovasc Dis. 2018;46:773–776.

Lu Duan. Practical Clinical Guidelines for the diagnosis and treatment of arrhythmias. Shanghai: Fudan University Press; 2003.

Chen W, Gao RL, Liu LS, et al. Summ China Cardiovasc Dis Report 2021. Ch Circ J. 2021;31:624–632.

Shen XL, Li L, Ma J, et al. Safety and efficacy of ultrafiltration on heart failure patients with reduced ejection fraction and diuretic resistance: results from a single-center randomized controlled trial. (In Chinese) Zhonghua Xin Xue Guan Bing Za Zhi. 2021;49:340–344. https://doi:10.3760/cma.j.cn112148-20200816-00646 . PubMed DOI

Lu Xiu-Yan, Lv Rong, Liang Tao. Current status of blood ultrafiltration therapy in patients with heart failure. (In Chinese) Chinese Circulation Journal. 2018:934–936.

Srivastava M, Harrison N, Caetano AFS, Tan AR, Law M. Ultrafiltration for acute heart failure. Cochrane Database Syst Rev. 2022;1:CD013593. doi: 10.1002/14651858.CD013593.pub2. PubMed DOI PMC

Li M, Yuan-Sheng L, Jian-Bo Y, Ji-Hong Z. Predictive value of NT-proBNP level and IVC-CI on volume load and prognosis in patients with acute heart failure. (In Chinese) J Med Postgraduates. 2020:289–295.

Huang Rong-Guo. Application of NT-proBNP and cTnI combined detection in diagnosis and treatment of patients with heart failure. (In Chinese) Prevention and Treatment of Cardiovascular Disease. 2020;10:43–45.

Schmitt W, Rühs H, Burghaus R, et al. NT-proBNP Qualifies as a surrogate for clinical end points in heart failure. Clin Pharmacol Ther. 2021;110:498–507. doi: 10.1002/cpt.2222. PubMed DOI PMC

Tian X-Q, Luo L, Ji X-P, Ye J-S. Effect of lyophilized recombinant human brain natriuretic peptide and levosimendan on the clinical efficacy and angiotensin II and endothelin in patients with acute decompensated heart failure. (In Chinese) Ch J Pharmaceutical Economics. 2020;15:78–81.

Sha H, Peng L. Effect of stepped pharmacologic therapy and ultrafiltration on the serum sodium in patients with acute heart failure. (In Chinese) J Clin Cardiol. 2019;35:848–853.

Bao QR, Li CY, Wang ZS. Clinical application of FQ-16 heart failure ultrafiltration dehydrating device combined with Levosimendan in the treatment of Stage III and IV chronic heart failure. Cardiovascular Disease (In Chinese) J Integrated Trad Chinese and Western Medicine. 2019;7:62–63.